Acute Myeloid Leukemia (AML)

High Risk MDS - 2025 Kansas City Patient and Family Conference

Topic(s)

Myelodysplastic Syndromes (MDS)

In this recording, Dr. Jesus Gonazlez Lugo discusses the diagnosis of High Risk MDS and the evolution to AML along with treatment options for patients. Recording includes the question-and-answer session.

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

Original Publication Date

April 17, 2025

Article Source

External Web Content

Abstract Hypomethylating agent (HMA) plus venetoclax (VEN) regimens are standard of care in patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. While the VEN label recommends continuous 28-day cycles, shortened VEN durations may induce similar…

2025 Boston Patient and Family Conference

Read more about 2025 Boston Patient and Family Conference

Session Recordings Available:

MDS to MPN Overlap from the 2025 Boston Patient and Family Conference

High Risk MDS from the 2025 Boston Patient and Family Conference

Low Risk MDS from the 2025 Boston Patient and Family Conference

2025 Chapel Hill Patient and Family Conference

Read more about 2025 Chapel Hill Patient and Family Conference

Recordings:

Transplant and GVHD Session - 2025 Kansas City Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Bone Marrow Transplant

In this recording, Dr. Anurag Singh discusses transplant and potentials complications such as GVHD and treatment options. Recording includes the question-and-answer session.

Living Well with Bone Marrow Failure, from the 2025 Kansas City Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Living Well with Bone Marrow Failure

Managing Your Treatment

In this recording, Dr. Furha Cossor discusses living with bone marrow failure and fatigue management. Recording includes the question-and-answer session.

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Read more about Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Urge your Members of Congress to Reverse the 57% Cut to the Congressionally Directed Medical Research Program

Original Publication Date

April 14, 2025

Article Source

Take Action

Federal budget negotiations are already under way. April 15 marks the 30-Day anniversary of the enactment of the 57% cut to CDMRP including the elimination of all funding to Bone Marrow Failure Research. Every medical research program at CDMRP directly impacts the health and…

2025 San Francisco - Bay Area Patient and Family Conference

Read more about 2025 San Francisco - Bay Area Patient and Family Conference

Recorded Sessions:

Nutrition for Aplastic Anemia, MDS, or PNH

Managing PNH Treatments

Advances in Aplastic Anemia

Secondary AML - Webinar 2025

Thumbnail for video Watch Now

Topic(s)

Acute Myeloid Leukemia (AML)

In this webinar, Drs. Fadi Haddad and Jayastu Senapati discuss the diagnosis secondary AML from MDS, treatment options available to patients and symptom management.

Subscribe to Acute Myeloid Leukemia (AML)

AAMDSIF Awareness Week

Acute Myeloid Leukemia (AML)

High Risk MDS - 2025 Kansas City Patient and Family Conference

Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients

2025 Boston Patient and Family Conference

2025 Chapel Hill Patient and Family Conference

Transplant and GVHD Session - 2025 Kansas City Patient and Family Conference

Living Well with Bone Marrow Failure, from the 2025 Kansas City Patient and Family Conference

Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia

Urge your Members of Congress to Reverse the 57% Cut to the Congressionally Directed Medical Research Program

2025 San Francisco - Bay Area Patient and Family Conference

Recorded Sessions:

Secondary AML - Webinar 2025

Website Feedback